IL315307A - Treatment methods using CTLA-4 and PD-1 bispecific antibodies - Google Patents

Treatment methods using CTLA-4 and PD-1 bispecific antibodies

Info

Publication number
IL315307A
IL315307A IL315307A IL31530724A IL315307A IL 315307 A IL315307 A IL 315307A IL 315307 A IL315307 A IL 315307A IL 31530724 A IL31530724 A IL 31530724A IL 315307 A IL315307 A IL 315307A
Authority
IL
Israel
Prior art keywords
ctla
bispecific antibodies
treatment methods
treatment
bispecific
Prior art date
Application number
IL315307A
Other languages
English (en)
Hebrew (he)
Inventor
Daniel J Freeman
Xuyang Song
Shelby Gainer
Deepa Subramaniam
Ikbel Achour
Charles Ferte
Original Assignee
Medimmune Llc
Daniel J Freeman
Xuyang Song
Shelby Gainer
Deepa Subramaniam
Ikbel Achour
Charles Ferte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Daniel J Freeman, Xuyang Song, Shelby Gainer, Deepa Subramaniam, Ikbel Achour, Charles Ferte filed Critical Medimmune Llc
Publication of IL315307A publication Critical patent/IL315307A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL315307A 2022-03-07 2023-03-06 Treatment methods using CTLA-4 and PD-1 bispecific antibodies IL315307A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263317200P 2022-03-07 2022-03-07
US202263347748P 2022-06-01 2022-06-01
US202263374815P 2022-09-07 2022-09-07
PCT/IB2023/052086 WO2023170549A1 (en) 2022-03-07 2023-03-06 Treatment methods using ctla-4 and pd-1 bispecific antibodies

Publications (1)

Publication Number Publication Date
IL315307A true IL315307A (en) 2024-10-01

Family

ID=87936206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315307A IL315307A (en) 2022-03-07 2023-03-06 Treatment methods using CTLA-4 and PD-1 bispecific antibodies

Country Status (9)

Country Link
US (1) US20230322928A1 (https=)
EP (1) EP4489781A4 (https=)
JP (1) JP2025508024A (https=)
KR (1) KR20240153603A (https=)
AU (1) AU2023231766A1 (https=)
CA (1) CA3253514A1 (https=)
IL (1) IL315307A (https=)
TW (1) TW202400656A (https=)
WO (1) WO2023170549A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
IL260021B (en) * 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
WO2021023117A1 (zh) * 2019-08-02 2021-02-11 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体及其用途
WO2023015292A1 (en) * 2021-08-06 2023-02-09 Xencor, Inc. Prostate cancer treatment or treatment of gynecologic or genitourinary malignancy with a bispecific antibody that binds ctla4 and pd1
TW202348788A (zh) * 2022-04-01 2023-12-16 美商藝康美國公司 協同防汙劑組成物及使用其之方法

Also Published As

Publication number Publication date
KR20240153603A (ko) 2024-10-23
US20230322928A1 (en) 2023-10-12
WO2023170549A1 (en) 2023-09-14
JP2025508024A (ja) 2025-03-21
AU2023231766A1 (en) 2024-10-17
TW202400656A (zh) 2024-01-01
CA3253514A1 (en) 2023-09-14
EP4489781A4 (en) 2026-03-25
EP4489781A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL291482A (en) Bispecific antibodies against ceacam5 and cd3
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
IL305827A (en) Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
IL299339A (en) Antibodies and methods for treating claudin-related diseases
IL286337A (en) Cancer treatment with her2xcd3 bispecific antibodies in combination with anti-her2 mab
SG11202108525VA (en) Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
IL304377A (en) Bispecific antibody targeting pd-1 and tim-3
CA3261147A1 (en) DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
IL315307A (en) Treatment methods using CTLA-4 and PD-1 bispecific antibodies
IL313864A (en) Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
IL312813A (en) Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
IL319877A (en) Methods for treating cancer with bispecific EGFR X CD28 antibodies alone or in combination with anti-PD-1 antibodies
CA3262914A1 (en) TREATMENT METHODS FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH ANTI-PSMA X ANTI-CD28 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
HK40082085A (en) Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
CA3291313A1 (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
HK40126940A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3261510A1 (en) DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
HK40117060A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
HK40121846A (en) Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3269085A1 (en) Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
HK40130891A (en) Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
IL316738A (en) Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
IL315770A (en) Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
HK40091622A (en) Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy